# GDFATHER-NEO (visugromab): what clinicians are saying

> 112 statements from 40 sources (1 podcast, 5 videos, 33 posts, 1 paper), 29 of them from 10 confirmed clinicians, each linked to its source. Commentary checked Nov 18, 2026.

## Report

- Trial: A Multi-center Phase 2 Study of Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for the Treatment of Muscle Invasive Bladder Cancer
- NCT ID: NCT06059547
- Registry: https://clinicaltrials.gov/study/NCT06059547
- Sponsor: CatalYm GmbH
- Phase: Phase 2
- Status: Completed
- Drugs tested: visugromab plus nivolumab
- Indication: muscle-invasive bladder cancer
- Version: v1.1.0, edition 2
- Accepted: 2026-11-18 UTC
- Last checked: 2026-11-18 UTC
- Release hash: c177f4922bb1964feb5b89d1939380fc79c95ec36f5bd62b19794815b9d06a15

## Counts

- Commentary sources screened: 70
- Sources cited by verified statements: 40
- Verified statements: 112
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 29
- Findings: 8
- Named people in screened sources (unnamed speakers and accounts not counted): 15
- Speakers cited: 15
- Cited speakers with a verified identity: 14
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 10
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 10
- By role and specialty (the abstract's specialty counts):
  - 6 physician, Medical oncology
  - 4 physician, specialty not confirmed
- Organisational or shared accounts (not counted as people): 5

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

One physician reads GDFATHER-NEO as warranting further investigation, not routine cystectomy avoidance, because pathological response need not translate into survival benefit. A speaker emphasizes response gains and describes tolerability favorably. Another physician questions the low nivolumab activity while cautioning against cross-trial comparisons. Recurrence-free observations concern only pathological complete responders, leaving durable bladder preservation uncertain.

## Question clinicians left open

What do clinicians say larger prospective trials with longer follow-up must establish about event-free survival and bladder preservation before considering cystectomy omission after neoadjuvant visugromab plus nivolumab in muscle-invasive bladder cancer?

From finding F1 (7 statements from 3 speakers in 4 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Cystectomy omission: why a clinician sees proof of concept as insufficient
  - 7 statements from 3 speakers in 4 sources, 1 of them a podcast or video.
  - 1 of the 3 named speakers in this finding holds this view, a confirmed clinician.
  - 1 of the report's 10 cited clinicians.
- F2. Response gap: most speakers limit inference; a clinician questions control responses
  - 10 statements from 5 speakers in 8 sources, 5 of them podcasts or videos.
  - 3 of the 5 named speakers in this finding hold this view; 1 of the 5 holds its caveat, “a clinician questions control responses”.
  - 2 of the report's 10 cited clinicians.
- F3. GDFATHER-NEO: what most speakers highlight in the size of the response difference
  - 14 statements from 8 speakers in 11 sources, 2 of them podcasts or videos.
  - 7 of the 8 named speakers in this finding hold this view.
  - 6 of the report's 10 cited clinicians.
- F4. Curative care: speakers note tolerability; one seeks no added toxicity
  - 7 statements from 4 speakers in 6 sources, 2 of them podcasts or videos.
  - 4 of the 4 named speakers in this finding hold this view; 1 of them holds its caveat, “one seeks no added toxicity”.
  - 1 of the report's 10 cited clinicians.
- F5. GDF-15 blockade: why a clinician would test biology-guided, less invasive treatment
  - 9 statements from 4 speakers in 5 sources, 3 of them podcasts or videos.
  - 1 of the report's 10 cited clinicians.
- F6. MIBC care: a speaker sees possible shifts; a clinician expects better results
  - 6 statements from 3 speakers in 4 sources.
  - 1 of the 3 named speakers in this finding holds this view; 1 of the 3 holds its caveat, “a clinician expects better results”.
  - 1 of the report's 10 cited clinicians.

### Beyond the trial population

- F7. GDF-15 combinations: how a speaker envisions de-escalation in deep responders
  - 7 statements from 2 speakers in 7 sources, 2 of them podcasts or videos.
  - 1 of the 2 named speakers in this finding holds this view.
  - No named clinician · accounts and unnamed speakers.
- F8. European clinical research: why a speaker calls for urgent changes
  - 2 statements from 1 speaker in 2 sources.
  - The one named speaker in this finding holds this view.
  - No named clinician · accounts and unnamed speakers.

2 of the 8 findings and 9 of the 112 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 7 | 4 | 4 | 3 | 2 |
| F2 | 10 | 8 | 8 | 5 | 2 |
| F3 | 14 | 11 | 11 | 8 | 3 |
| F4 | 7 | 7 | 6 | 4 | 3 |
| F5 | 9 | 6 | 5 | 4 | 2 |
| F6 | 6 | 4 | 4 | 3 | 4 |
| F7 | 7 | 7 | 7 | 2 | 3 |
| F8 | 2 | 2 | 2 | 1 | 1 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 4 | 1 | 0 | 0 | 2 | 7 | 1 | 3 posts and articles, 1 podcast or video |
| F2 | 4 | 0 | 0 | 1 | 5 | 12 | 2 | 2 posts and articles, 5 podcasts and video, 1 publication |
| F3 | 9 | 0 | 0 | 2 | 3 | 15 | 2 | 8 posts and articles, 2 podcasts and video, 1 publication |
| F4 | 5 | 0 | 0 | 0 | 2 | 8 | 1 | 3 posts and articles, 2 podcasts and video, 1 publication |
| F5 | 6 | 1 | 0 | 1 | 1 | 9 | 1 | 2 posts and articles, 3 podcasts and video |
| F6 | 3 | 1 | 0 | 0 | 2 | 6 | 3 | 4 posts and articles |
| F7 | 7 | 0 | 0 | 0 | 0 | 7 | 0 | 5 posts and articles, 2 podcasts and video |
| F8 | 2 | 0 | 0 | 0 | 0 | 2 | 0 | 2 posts and articles |

### Trial dimensions

- Primary endpoint: Pathological complete response rate: F1 (1 shared claims), F2 (2 shared claims), F3 (7 shared claims), F4 (2 shared claims)
- Primary endpoint: Radiological response rate according RECIST: F1 (1 shared claims), F2 (2 shared claims), F3 (5 shared claims), F4 (1 shared claims)
- Secondary endpoints: F1 (2 shared claims), F3 (2 shared claims), F4 (2 shared claims), F5 (2 shared claims)
- Population and setting: F2 (2 shared claims), F5 (3 shared claims), F6 (2 shared claims)
- The comparison: F1 (1 shared claims), F2 (9 shared claims), F3 (9 shared claims), F4 (1 shared claims), F6 (1 shared claims)
- Safety and tolerability: F1 (1 shared claims), F2 (1 shared claims), F3 (4 shared claims), F4 (6 shared claims)
- Design and conduct: F1 (1 shared claims), F2 (6 shared claims), F3 (2 shared claims), F4 (1 shared claims), F6 (1 shared claims)

## Abbreviations

- HCP: healthcare professional
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians
- RECIST: Response Evaluation Criteria in Solid Tumors

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 8 | Titles free |
| Detailed analysis | 10 sections | Paid |
| Verified statements with short source quotes and links | 112 | Paid |
| Who said each statement: the cited speakers | 15 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 10 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 14 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 13 | Free |
| Sources with links | 40 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 10 of the 15 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

13 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Pathological complete response rate | discussed | 28 | 26 |
| Primary endpoint: Radiological response rate according RECIST | discussed | 20 | 19 |
| Secondary endpoints | discussed | 23 | 14 |
| Population and setting | discussed | 16 | 11 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 35 | 24 |
| Safety and tolerability | discussed | 24 | 20 |
| Design and conduct | discussed | 17 | 15 |
| Response-conditioned bladder preservation and limits on changing surgery | discussed | 19 | 12 |
| Immune-resistance rationale and investigational biological selection | discussed | 20 | 10 |
| Neoadjuvant MIBC positioning amid evolving perioperative alternatives | discussed | 8 | 5 |
| Untested combinations and proposed de-escalation in deep responders | discussed | 7 | 7 |
| European clinical-research environment | discussed | 2 | 2 |
| Study novelty, evaluative reactions and wider GDF-15 visibility | discussed | 11 | 7 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 44 statements · 39%** | | | |
| YouTube | 39 | 5 | 5 |
| Podcasts | 5 | 1 | 1 |
| **Posts · 65 statements · 58%** | | | |
| X threads | 40 | 24 | 52 |
| LinkedIn posts | 21 | 6 | 7 |
| Bluesky threads | 4 | 3 | 5 |
| **Primary sources · 3 statements · 3%** (cited for context, not screened) | | | |
| Publications (primary source, cited for context) | 3 | 1 | not screened |

- Screened window: 2024-01-27 to 2026-11-09
- Cited window: 2025-09-23 to 2026-11-09
- Retrieved: 2026-11-17

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Multi-center Phase 2 Study of Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for the Treatment of Muscle Invasive Bladder Cancer
- Registry: NCT06059547 (https://clinicaltrials.gov/study/NCT06059547)
- Study IDs: CTL-002-002
- Sponsor: CatalYm GmbH
- Design: Phase 2 · interventional, non randomized, parallel, phase2
- Status: Completed
- Enrollment: 31 (actual)
- Start: 2023-09-06 (actual)
- Primary completion: 2025-10-16 (actual)
- Primary endpoint: Pathological complete response rate (min. 4 months)
- Primary endpoint: Radiological response rate according RECIST (min. 4 months)
- Intervention: Nivolumab (drug)
- Intervention: Visugromab (CTL-002) (drug)
- Intervention: Placebo (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on integrating circulating and urinary tumour DNA to predict response and recurrence after neoadjuvant bladder cancer therapy; a view on ctDNA and utDNA for predicting pathological response and recurrence-free survival after neoadjuvant treatment in muscle-invasive bladder cancer.
- 45 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 6 sources about other trials or topics are not included.
- The sources reviewed for this edition are not a representative sample of HCP opinion. Organizational accounts, congratulatory reactions, relays and repeated versions of discussions should not be counted as independent clinician endorsements.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- The publication describes nonrandomized allocation, whereas some interview accounts say randomized. Response labels, major-response rates and control percentages also vary between accounts; these differences prevent a single harmonized rendering of what everyone reported.
- Favorable recurrence follow-up is restricted to response-defined subgroups and remains short. It does not establish a whole-population survival advantage or the long-term safety of bladder preservation.
- Coverage concentrated on trial names and identifiers. Relevant discussion using unnamed references, variant spellings or different transcription may be absent.
- No trial protocol or exact regulatory label for visugromab was available among the sources reviewed. This limits detailed assessment of methods and regulatory positioning; it does not establish the drug's regulatory status.
- Expectations about later presentations or readouts are preserved at the timing stated in the sources and are not evidence of what those later studies showed.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.1.0, edition 2, accepted 2026-11-18 UTC: current edition
- v1.0.0, edition 1: replaced by edition 2

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-18 UTC. No changes.

## Offer

- Size: Focused · 112 verified statements · 29 from 10 confirmed clinicians
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $1,300
- 6 months of updates: $1,900
- 12 months of updates: $2,600
- Every product includes verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself (14 identity-verified speakers now); social accounts are not included. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/gdfather-neo-nct06059547
- Agents: POST https://www.erudio.com/api/orders with {"report": "gdfather-neo-nct06059547", "product": "edition" | "updates-3" | "updates-6" | "updates-12", "buyer_email": "...", "organization": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user and a pay_url your own payment client can pay over HTTP 402 in USDC, with MPP (on Tempo) or x402 (on Base), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=gdfather-neo-nct06059547

## Cite

Erudio Health. GDFATHER-NEO (NCT06059547): HCP commentary report. Edition 2, v1.1.0. Accepted Nov 18, 2026. https://www.erudio.com/reports/gdfather-neo-nct06059547

## Questions

### How much does the GDFATHER-NEO report cost?

One edition costs $750 (Focused · 112 verified statements · 29 from 10 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.

### What does the GDFATHER-NEO report cover?

112 statements from 40 sources (1 podcast, 5 videos, 33 posts, 1 paper), 29 of them from 10 confirmed clinicians, each linked to its source. Commentary checked Nov 18, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the GDFATHER-NEO report?

Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "gdfather-neo-nct06059547" }) previews it and create_order({ "report": "gdfather-neo-nct06059547", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the GDFATHER-NEO report?

Edition 2 (version 1.1.0), accepted Nov 18, 2026 UTC; last checked for new commentary Nov 18, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/gdfather-neo-nct06059547.json
- Markdown: https://www.erudio.com/reports/gdfather-neo-nct06059547.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/gdfather-neo-nct06059547/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "gdfather-neo-nct06059547"}`
